WV

WAVE Life Sciences LtdNASDAQ WVE Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

1.022

Small

Exchange

XNAS - Nasdaq

WVE Stock Analysis

WV

Uncovered

WAVE Life Sciences Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-5/100

Low score

Market cap $B

1.022

Dividend yield

Shares outstanding

86.91 B

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. The company employs 235 full-time employees The company went IPO on 2015-11-11. The company is engaged in developing oligonucleotides that target ribonucleic acid (RNA) and harness existing cellular machinery to reduce the expression of disease-promoting RNA or proteins, restore the production of functional proteins, or modulate protein expression. Its lead clinical development programs are designed to treat genetic diseases within the central nervous system (CNS), including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington’s disease (HD), and muscular dystrophies, including Duchenne muscular dystrophy (DMD). Its programs include WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated ALS and FTD, WVE-003 (silencing), its mHTT SNP3 molecule for the treatment of HD, and WVE-N531 (splicing), its exon 53 molecule for the treatment of DMD.

View Section: Eyestock Rating